Britain and America have agreed to a key trade agreement that will preserve no import taxes on British drug products going into the American market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to increase spending on medicines through the NHS. This pledge ensures that tariffs on these key exports will remain at zero for a duration of 36 months.
This agreement comes after recent statements to dramatically increase import taxes on patented pharmaceutical imports, with figures mentioned as high as 100%.
"This agreement between the United Kingdom strengthens the international landscape for new treatments and brings much-needed fairness to American-British drug exports," a statement declared.
Trade Importance
Drugs represent one of the UK's biggest exports to the America, which is by far the largest buyer for large companies like GSK and AstraZeneca.
Export figures show that in the one-year period to the end of last September, the UK shipped drugs totaling over eleven billion pounds to the US. This amount accounted for a significant portion of total UK exports in that period.
"This guarantee secures work, boosts capital expenditure and sets the stage for the UK to emerge as a international leader for medical research," a minister stated.
Specific NHS Changes
The deal involves several specific changes from the UK:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new treatments to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to increase overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The sum manufacturers must refund to the NHS to stay within budget will be restricted at fifteen percent. In the past, rebates topped twenty percent.
Recent Tensions
The pact follows a ongoing tension between the sector and the British authorities over drug pricing and regulatory access.
These tensions were intensified by claims that American customers were charged several times more for the identical medicines than people in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been paused or abandoned, while substantial expansions have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a percentage of its resources over the last ten years.
